Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Summary

This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening condition.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications